{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-068584","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.085480+00:00","generated_at":"2026-06-18T04:32:51.813174+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"ARS Pharmaceuticals updates corporate presentation; no material new details disclosed","bullets":["Filed a Form 8-K on March 13, 2023, to furnish an updated corporate presentation.","Presentation highlights neffy as 'first no-needle, no-injection solution' for Type I allergic reactions.","No financial, clinical, or regulatory milestones were reported in the filing or the title slide of Exhibit 99.1.","Presentation is available on the company's website; content beyond the title slide is not provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-068584","json":"https://secwatch.observer/filing/0001193125-23-068584.json","markdown":"https://secwatch.observer/filing/0001193125-23-068584.md","text":"https://secwatch.observer/filing/0001193125-23-068584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312523068584/0001193125-23-068584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312523068584/d444956d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:32:51.813174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}